Ranbaxy Laboratories Inc. Implements Cegedim Relationship Management’s Compliance Solution Suite to Efficiently Meet Regulatory Requirements

Cegedim Relationship Management today announced that Ranbaxy Laboratories Inc. has fully deployed the company’s groundbreaking Life Sciences compliance solution suite, including the market leading AggregateSpend360™, to more efficiently, proactively and successfully respond to today’s compounding regulatory environment. Ranbaxy Laboratories Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is engaged in the sale and distribution of branded prescription products in the U.S. healthcare system.

AggregateSpend360 Enables Dramatically Increased Data Visibility and Features Tailored to Compliance Functionalities

To satisfy the Sunshine Provisions of the Patient Protection and Affordable Care Act (PPACA), leading Life Sciences companies are focusing on effectively managing their brands, and connecting with targets across both pharmacy and prescription channels.

AggregateSpend360 alleviates Ranbaxy’s resources and time spent meeting the PPACA’s state/federal aggregate spend and disclosure reporting requirements. The solution collects and centralizes all transfers of value to practitioners – rationalizing the data into one customer view for optimal visibility. The cloud-based solution generates reports specific to each federal/state regulation. Further, the solution features unparalleled configuration flexibility to suit Ranbaxy’s distinctive business model needs, fostering cost-effectiveness now and in the future. AggregateSpend360 fully automates the compliance burden.

Customer Licensure and System Validation Provide Valuable Certainty of Database Quality and Network Effectiveness

Ranbaxy’s compliance solution suite also includes Cegedim’s Compliance ID Powered by OneKey™, which empowers companies to satisfy aggregate spend and disclosure reporting regulations through verified medical licensure information sourced from OneKey’s database of 12 million registered HCPs and one million healthcare organizations. Ranbaxy is also leveraging Cegedim’s BuzzeoPDMA compliance knowledge through Computer Systems Validation Services, which confirm that systems satisfy both state and federal regulatory standards.

"By aligning with Cegedim’s AggregateSpend360 and their compliance suite, we are staying well ahead of the curve regarding new U.S. legislation. Teams across the U.S enterprise – Primary Care, KOLs, Home Office, IT and Compliance teams – are now empowered with the tools to better track spending, improve data, and ensure that our technology is fully compliant,” said Dr. Ashish Anvekar, Senior Director of Ranbaxy Laboratories Inc. "Our company can achieve greater focus in providing patient-centric, quality and value-added pharmaceuticals.”